Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: BioCardia is a clinical-stage biotechnology company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous mononuclear cell therapy for ischemic heart failure and chronic myocardial ischemia, and an allogeneic mesenchymal stem cell (MSC) therapy. The company also develops the Helix transendocardial biotherapeutic delivery system.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $58 |
| Net Loss | $(1,483) | $(1,737) | $(6,244) | $(5,650) |
| Operating Loss | $(1,488) | $(1,756) | $(6,265) | $(5,680) |
| Net Loss Per Share (Basic/Diluted) | $(0.24) | $(0.61) | $(1.17) | $(2.65) |
| Cash and Cash Equivalents (End of Period) | $5,287 | $4,930 | $5,287 | $4,930 |
| Accumulated Deficit | $(166,365) | $(157,825) | $(166,365) | $(157,825) |
| Net Cash Used in Operating Activities (9M) | $(4,939) | $(5,453) | $(4,939) | $(5,453) |
| Net Cash Provided by Financing Activities (9M) | $7,856 | $9,285 | $7,856 | $9,285 |
Liquidity: As of September 30, 2025, the company held $5.3 million in cash. Management states this is insufficient to fund operations beyond the second quarter of 2026 without additional capital.
Material Changes vs. Prior Period
- Revenue: No revenue was recognized in Q3 or the nine months ended September 30, 2025, compared to $58,000 in the prior year nine-month period.
- Expenses:
- R&D: Increased to $3.8 million for the nine months ended Sept 30, 2025, from $3.0 million in the prior year period, driven by closeout activities for the CardiAMP Heart Failure Trial and enrollment in the CardiAMP HF II Trial.
- SG&A: Decreased to $2.4 million for the nine months ended Sept 30, 2025, from $2.8 million in the prior year, primarily due to lower professional service fees and share-based compensation.
- Capital Structure: Significant equity dilution occurred through multiple financings in 2025, including a September 2025 offering raising $6.0 million and ATM sales. Outstanding common shares increased from 4.6 million (Dec 31, 2024) to 10.6 million (Sept 30, 2025).
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern beyond one year due to recurring losses and negative cash flows. Additional funding is required to continue operations past Q2 2026.
- Clinical Progress:
- CardiAMP HF: Two-year results showed statistically significant composite endpoints in patients with elevated NTproBNP. The company expects to submit data to the FDA in Q4 2025.
- CardiAMP HF II: Enrollment has commenced in this 250-patient Phase 3 trial.
- Japan: A positive preliminary consultation with the PMDA was held; a formal consultation is expected late in 2025 to enable market entry submission.
- Regulatory Risk (Form S-3): The company is currently unable to utilize Form S-3 for registered offerings due to a filing error in August 2025. This limitation restricts the use of the At-The-Market (ATM) program and may delay or increase the cost of future capital raises until a waiver is obtained or eligibility is regained (potentially not until Sept 2026).
- Delisting Risk: The company notes that failure to maintain Nasdaq listing requirements could result in delisting, though it has currently regained compliance.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the Q2 2026 liquidity horizon and the inability to use Form S-3.
- Dilution Impact: Assess the impact of the recent September 2025 offering ($6M gross proceeds) and the increase in outstanding shares to 10.6 million on existing shareholder value.
- Form S-3 Status: Monitor SEC communications regarding the waiver for Form S-3 eligibility, as this is critical for efficient future fundraising.
- Clinical Milestones: Track the Q4 2025 FDA meeting request regarding the CardiAMP HF data and the enrollment progress of the CardiAMP HF II trial.
- Revenue Recognition: Confirm if any collaboration revenues or product sales (e.g., Morph DNA) will materialize in the coming quarters to offset operating losses.